Next Article in Journal
Mechanisms and Therapeutic Implications of Cell Death Induction by Indole Compounds
Next Article in Special Issue
Immunotherapy for Urothelial Carcinoma: Current Status and Perspectives
Previous Article in Journal
Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications
Previous Article in Special Issue
Two Domains of Vimentin Are Expressed on the Surface of Lymph Node, Bone and Brain Metastatic Prostate Cancer Lines along with the Putative Stem Cell Marker Proteins CD44 and CD133
Cancers 2011, 3(3), 2904-2954; doi:10.3390/cancers3032904
Review

Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines

,
,
 and *
Received: 26 May 2011; in revised form: 1 July 2011 / Accepted: 7 July 2011 / Published: 18 July 2011
(This article belongs to the Special Issue Cancer Vaccines and Immunotherapy)
View Full-Text   |   Download PDF [357 KB, updated 20 July 2011; original version uploaded 18 July 2011]
Abstract: Human tumors are usually not spontaneously eliminated by the immune system and therapeutic vaccination of cancer patients with defined antigens is followed by tumor regressions only in a small minority of the patients. The poor vaccination effectiveness could be explained by an immunosuppressive tumor microenvironment. Because T cells that infiltrate tumor metastases have an impaired ability to lyse target cells or to secrete cytokine, many researchers are trying to decipher the underlying immunosuppressive mechanisms. We will review these here, in particular those considered as potential therapeutic targets. A special attention will be given to galectins, a family of carbohydrate binding proteins. These lectins have often been implicated in inflammation and cancer and may be useful targets for the development of new anti-cancer therapies.
Keywords: anergy; immunosuppression; cancer vaccines; galectin; tumor-infiltrating lymphocytes anergy; immunosuppression; cancer vaccines; galectin; tumor-infiltrating lymphocytes
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Wieërs, G.; Demotte, N.; Godelaine, D.; Van der Bruggen, P. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers 2011, 3, 2904-2954.

AMA Style

Wieërs G, Demotte N, Godelaine D, Van der Bruggen P. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. Cancers. 2011; 3(3):2904-2954.

Chicago/Turabian Style

Wieërs, Grégoire; Demotte, Nathalie; Godelaine, Danièle; Van der Bruggen, Pierre. 2011. "Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines." Cancers 3, no. 3: 2904-2954.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert